Bio-Rad Laboratories

Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024

Retrieved on: 
Giovedì, Maggio 9, 2024
Singular, Labroots, Genetics, Genomics, DSM-IV codes, Mass, Networking hardware, Travel, Health, QIAGEN, Doctor of Philosophy, Research, Gene, Scale, NGS, Knowledge, Entrepreneurship, Future, Bio-Rad Laboratories, Algorithm, Diagnosis, History, MPH, Harvard Medical School, Mass General Brigham, Genetic testing, Thermo Fisher Scientific, Vaccine

YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series. This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.

Key Points: 
  • Join Labroots on May 15, 2024, for the 12th Annual Precision Medicine Virtual Event Series, exploring the latest in genomics, genetics, and molecular diagnostics, with keynote speakers, dynamic sessions, and opportunities for continuing education.
  • YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series .
  • This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.
  • This year's event will dive deep into the cutting-edge areas of genomics, genetics, and molecular diagnostics, pivotal in the ongoing revolution of personalized healthcare.

Bio-Rad Reports First-Quarter 2024 Financial Results

Retrieved on: 
Martedì, Maggio 7, 2024
Biotechnology, Diabetes, Health, Other Health, Pharmaceutical, Stem Cells, Research, Medical Devices, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Acquisition, Table, Webcast, Bank statement, Forecasting, Nature, GAAP, Growth, EPS, Bio-Rad Laboratories, Bank

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Key Points: 
  • A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
  • Management will discuss the company’s first quarter 2024 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on May 7, 2024.
  • There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies.
  • The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.

Europe In-Vitro Diagnostics (IVD) Market Insights 2024-2029: Increasing Adoption of Automation in Laboratories, Growing Importance for Personalised Medicine - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Maggio 6, 2024
Health, Biotechnology, Conditional sentence, EP, Pandemic, Automation, Risk, Thermo Fisher Scientific, Hematology, Siemens Healthineers, Research, Calibration, Abbott Laboratories, Infection, Partnership, Bio-Rad Laboratories, Documentation, 2005 in television, Medicine, Diagnosis, Ageing, Diabetes, Molecular biology, COVID-19, IVD, Growth, Prevalence, Medical device

Europe's in-vitro diagnostics (IVDs) market is expected to grow at a CAGR of 2.23% from 2023 to 2029.

Key Points: 
  • Europe's in-vitro diagnostics (IVDs) market is expected to grow at a CAGR of 2.23% from 2023 to 2029.
  • Vendors in the market are increasing their market share through inorganic growth.
  • Spain shows the highest growth rate, with a CAGR of 3% in Europe's in-vitro diagnostics (IVDs) market.
  • By end-user, the standard reference labs segment dominated the market share of the Europe in-vitro diagnostics (IVDs) market.

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Venerdì, Maggio 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Venerdì, Maggio 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Seven Corporate Buyers Enter Into Aggregation Deal To Purchase 180 MW of Solar Energy Through the Net Zero Consortium for Buyers

Retrieved on: 
Mercoledì, Maggio 1, 2024
Negotiation, Sustainable business, Cisco, Sustainability, Laboratory, Health, Software, Partnership, Electricity, ERCOT, Research, VPPA, Gamer, Bio-Rad Laboratories, Idexx Laboratories, Duke Energy, Multimedia, Cadence Design Systems, PTC, Renewable energy

The seven buyers signed VPPAs to develop new renewable energy capacity in the ERCOT region of Texas through SR Inc's NZCB.

Key Points: 
  • The seven buyers signed VPPAs to develop new renewable energy capacity in the ERCOT region of Texas through SR Inc's NZCB.
  • The buyer-aggregated approach democratizes access to the commercial and environmental benefits of utility-scale renewable energy by making procurement accessible to a broader range of enterprises.
  • Finally, a large healthcare company will purchase renewable energy generated from the remaining 20 MW portion of Millers Branch.
  • SR Inc's Net Zero Consortium for Buyers (NZCB) is a confidential buyers' community committed to creating corporate buyer-favorable renewable energy transactions that enable participating enterprises to chart a profitable path to Net Zero emissions globally.

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Sabato, Aprile 27, 2024
Use, Polycystic ovary syndrome, Ovarian reserve, PCOS, WHO, Hormone, Danaher Corporation, Primary ovarian insufficiency, Health, World Health Organization, Woman, Infertility, Anti-Müllerian hormone, Health care, AMH, Fertility, Table, Intelligence, IVF, Bio-Rad Laboratories, Privacy, Thermo Fisher Scientific, Diagnosis, POC, Growth, Birth control

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.

Key Points: 
  • Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.
  • A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market.
  • "Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures"

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Sabato, Aprile 27, 2024
Use, Polycystic ovary syndrome, Ovarian reserve, PCOS, WHO, Hormone, Danaher Corporation, Primary ovarian insufficiency, Health, World Health Organization, Woman, Infertility, Anti-Müllerian hormone, Health care, AMH, Fertility, Table, Intelligence, IVF, Bio-Rad Laboratories, Privacy, Thermo Fisher Scientific, Diagnosis, POC, Growth, Birth control

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.

Key Points: 
  • Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.
  • A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market.
  • "Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures"

Oncocyte Reports Full Year 2023 Financial Results

Retrieved on: 
Venerdì, Aprile 12, 2024
Kidney, IP, Bio-Rad Laboratories, Research, Security (finance), Partnership, OCX, Eastern Time Zone, Marketing, Telephone, Cryptocurrency

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.

Key Points: 
  • IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.
  • Q1 2024 cash burn, respectively
    “In 2023, we made significant progress on cost controls and in the development of our transplant monitoring IP,” said Josh Riggs, CEO of Oncocyte.
  • For Oncocyte’s complete financial results for the year ended December 31, 2023, see the Company’s annual Form 10-K to be filed with the Securities and Exchange Commission on April 15, 2024.
  • Oncocyte will host a conference call to discuss fourth quarter and full year 2023 financial results prior to market open on Friday, April 12, 2024 at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

Retrieved on: 
Giovedì, Aprile 11, 2024
FDA, Bio-Rad Laboratories, Security (finance), Partnership, Research, DdPCR, PCR, Transplant, OCX, IVD, Pharmaceutical industry

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the commercialization of its research use only GraftAssure™ assay, powered by Droplet Digital™ PCR (ddPCR™)*. The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year.

Key Points: 
  • The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year.
  • As part of the agreement, Bio-Rad and Oncocyte will co-market the assay inside the US and Germany, with Oncocyte acting as commercial lead.
  • Outside these countries Bio-Rad has been granted exclusive global distribution and commercial rights.
  • Additionally, Bio-Rad has been granted an option for IVD commercial rights at FDA clearance, subject to meeting specific objectives.